JP2022512770A5 - - Google Patents

Info

Publication number
JP2022512770A5
JP2022512770A5 JP2021521472A JP2021521472A JP2022512770A5 JP 2022512770 A5 JP2022512770 A5 JP 2022512770A5 JP 2021521472 A JP2021521472 A JP 2021521472A JP 2021521472 A JP2021521472 A JP 2021521472A JP 2022512770 A5 JP2022512770 A5 JP 2022512770A5
Authority
JP
Japan
Prior art keywords
peptide
cxcl
amino acid
recombinant
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7426121B2 (ja
JP2022512770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056955 external-priority patent/WO2020086400A1/en
Publication of JP2022512770A publication Critical patent/JP2022512770A/ja
Publication of JP2022512770A5 publication Critical patent/JP2022512770A5/ja
Priority to JP2023198254A priority Critical patent/JP7798368B2/ja
Application granted granted Critical
Publication of JP7426121B2 publication Critical patent/JP7426121B2/ja
Priority to JP2025145434A priority patent/JP2025172140A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521472A 2018-10-22 2019-10-18 Cxcr3の切断可能な活性化因子および使用方法 Active JP7426121B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023198254A JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法
JP2025145434A JP2025172140A (ja) 2018-10-22 2025-09-02 Cxcr3の切断可能な活性化因子および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198254A Division JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法

Publications (3)

Publication Number Publication Date
JP2022512770A JP2022512770A (ja) 2022-02-07
JP2022512770A5 true JP2022512770A5 (cg-RX-API-DMAC7.html) 2022-10-17
JP7426121B2 JP7426121B2 (ja) 2024-02-01

Family

ID=70330587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021521472A Active JP7426121B2 (ja) 2018-10-22 2019-10-18 Cxcr3の切断可能な活性化因子および使用方法
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法
JP2025145434A Pending JP2025172140A (ja) 2018-10-22 2025-09-02 Cxcr3の切断可能な活性化因子および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法
JP2025145434A Pending JP2025172140A (ja) 2018-10-22 2025-09-02 Cxcr3の切断可能な活性化因子および使用方法

Country Status (12)

Country Link
US (2) US12110316B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870212A4 (cg-RX-API-DMAC7.html)
JP (3) JP7426121B2 (cg-RX-API-DMAC7.html)
KR (2) KR102984527B1 (cg-RX-API-DMAC7.html)
CN (2) CN113038965B (cg-RX-API-DMAC7.html)
AU (2) AU2019365654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007414A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116325A1 (cg-RX-API-DMAC7.html)
IL (2) IL282431B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004496A (cg-RX-API-DMAC7.html)
SG (1) SG11202103497WA (cg-RX-API-DMAC7.html)
WO (1) WO2020086400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103497WA (en) * 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
US20260201006A1 (en) * 2022-11-30 2026-07-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
CA2525647A1 (en) * 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
WO2015021058A2 (en) * 2013-08-05 2015-02-12 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
EP3096777B1 (en) * 2014-01-21 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Goblet cell replacement therapy
EA035259B1 (ru) * 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
AU2017364818C1 (en) * 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
SG11202103497WA (en) 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use

Similar Documents

Publication Publication Date Title
CN108348580B (zh) 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
US9682153B2 (en) Polymer conjugates of therapeutic peptides
AU2016274175B2 (en) Methods and polypeptides for modulation of immunoresponse
AU2017295708B2 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
AU783479B2 (en) Cell permeable peptides for inhibition of inflammatory reactions and methods of use
TW202140517A (zh) 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途
JP2025172140A5 (cg-RX-API-DMAC7.html)
AU2018210174A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20040235746A1 (en) Cell permeable peptides for inhibition of inflammatory reactions and methods of use
JP2011518179A5 (cg-RX-API-DMAC7.html)
DK3045183T3 (en) PEGYLED APELIN AND APPLICATIONS THEREOF
US20240270808A1 (en) MANP Analogues
JP7798368B2 (ja) Cxcr3の切断可能な活性化因子および使用方法
US12241099B2 (en) Peptide therapeutics for treating Alzheimer's disease and related conditions
WO2020093789A1 (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
CN115803338A (zh) C型利尿钠肽及其治疗急性肺损伤的方法
WO2020073825A1 (zh) 一种改善生物活性蛋白性质的载体蛋白
CA2459230A1 (en) Peptidic compounds selectively binding to p-selectin
CN115605218A (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
HK40123732A (en) Cleavable activators of cxcr3 and methods of use
CN110139659A (zh) 用于治疗干燥综合征的肽
WO2025001976A1 (zh) 新型补体抑制剂及其制备、应用和产品
WO2025096051A1 (en) Miniaturized gc-a receptor activating peptides
CN116322738A (zh) 血管加压素-2受体拮抗肽及其用途
WO2025226690A1 (en) Methods and materials for using gc-a receptor activating peptides in combination with glp-1/gip receptor agonists